SequelSEC

SAB Biotherapeutics, Inc. SABS

Biological Products, (No Diagnostic Substances) · CIK 0001833214 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from SAB Biotherapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

SAB Biotherapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
RevenueUnavailable$114.70K$0$263.14K$944.58K$305.01K$1.27M$85.52K$581.10K$2.16M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailable-$10.01M-$11.31M-$10.20M-$11.39M-$18.87M-$5.32M-$6.48M-$7.40M-$7.86M
Net incomeUnavailable-$11.39M-$10.35M-$7.34M-$5.03M-$22.86M-$5.10M-$6.88M-$7.35M-$7.87M
Research & developmentUnavailable$7.65M$7.83M$6.82M$8.15M$4.30M$4.02M$3.66M$4.54M$7.14M
Weighted-average diluted sharesUnavailableUnavailableshares 9.26Mshares 9.26Mshares 9.24MUnavailableshares 5.24Mshares 5.04Mshares 5.04MUnavailable
Pretax incomeUnavailableUnavailable-$10.35M-$7.34M-$5.03M-$22.86M-$5.10M-$6.88M-$7.35M-$7.85M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0Unavailable
Diluted EPSUnavailableUnavailable$-1.12$-0.79$-0.54Unavailable$-0.97$-1.36$-1.46Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailable$2.47M$3.48M$3.64M$4.19M$14.88M$2.57M$2.90M$3.45M$2.88M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

SAB Biotherapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Cash & equivalents$10.50M$8.90M$9.17M$17.24M$14.03M$56.57M$2.43M$7.77M$13.06M$15.05M
Total assets$172.81M$44.20M$53.80M$61.89M$71.37M$83.94M$28.34M$35.44M$42.67M$50.90M
Current assets$101.05M$23.79M$32.54M$39.58M$46.95M$58.91M$3.13M$9.01M$15.03M$22.10M
Total liabilities$21.32M$18.23M$16.89M$15.77M$18.55M$26.64M$13.08M$15.73M$18.27M$19.85M
Current liabilities$10.68M$7.98M$8.82M$7.55M$8.30M$10.81M$9.21M$11.01M$13.67M$14.99M
Total equity incl. NCI$151.50M$25.97M$36.90M$46.12M$52.82M$57.30M$15.26M$19.72M$24.40M$31.06M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$364.12K$763.12K$5.56M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.15M$1.69M$1.30M$1.17M$1.24M$945.93K$1.08M$1.40M$1.44M$3.68M

Cash flow

SAB Biotherapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Operating cash flowUnavailable-$9.53M-$6.29M-$7.72M-$10.75M-$13.45M-$5.17M-$4.90M-$1.61M-$1.56M
Capital expendituresUnavailable$55.38K$100.30K$52.51K$129.07K$67.86K$85.31K$22.68K$21.30K$117.75K
Investing cash flowUnavailable$9.33M-$1.15M$11.22M-$31.36M-$67.86K-$40.86K-$22.68K-$21.30K-$117.75K
Financing cash flowUnavailable$216.96K-$674.13K-$321.04K-$394.42K$67.64M-$140.31K-$363.79K-$359.79K$8.39M
Net change in cashUnavailable-$273.21K-$8.07M$3.21M-$42.53M$54.14M-$5.35M-$5.29M-$1.99M$6.71M
Stock-based compensationUnavailable$674.14K$1.05M$601.43K$617.44K$536.88K$639.25K$644.82K$602.78K$628.54K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$764.01K$900.00K$1.00M$1.96M$922.49K$1.00M$900.00K$898.45K$898.81K

Derived

SAB Biotherapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
Free cash flowUnavailable-$9.59M-$6.39M-$7.77M-$10.88M-$13.51M-$5.25M-$4.92M-$1.63M-$1.67M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-8726.3%Unavailable-3877.0%-1205.9%-6187.9%-420.0%-7573.4%-1273.8%-363.7%
FCF marginUnavailable-8359.0%Unavailable-2952.9%-1151.7%-4430.9%-414.5%-5755.3%-280.0%-77.4%
SBC / revenueUnavailable587.7%Unavailable228.6%65.4%176.0%50.4%754.0%103.7%29.1%
Current ratio9.46x2.98x3.69x5.24x5.65x5.45x0.34x0.82x1.10x1.47x
Revenue YoY growthUnavailable-62.4%-100.0%207.7%62.5%-85.9%-64.7%-98.7%-95.1%-80.5%
Net marginUnavailable-9934.5%UnavailableUnavailableUnavailable-7493.8%-402.6%UnavailableUnavailable-364.4%
R&D / revenueUnavailable6671.1%Unavailable2592.6%862.4%1408.9%317.2%4282.3%780.5%330.3%
CapEx / revenueUnavailable48.3%Unavailable20.0%13.7%22.2%6.7%26.5%3.7%5.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SABS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2021-09-30

Difference 44371339 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2021-06-30

Difference 33258535 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.